November 7, 2024
We invite you to join this KOL webinar featuring two globally recognized U.S. pulmonology experts to get their views on the data from REALITY and how eyonis™ LCS may impact lung cancer diagnostics and treatment practices in the real world. Panelists include Prof. Anil Vachani, from the Hospital of the University of Pennsylvania, and Prof. Javier Zulueta, from the Icahn School of Medicine at Mt Sinai. Fredrik Brag, CEO of Median Technologies, also will participate and summarize the final REALITY results, which are going to be submitted in H1 2025 to regulators for U.S. and EU marketing authorizations for eyonis™ LCS.
We are helping conquer cancer and fibrotic diseases by extracting invaluable clinical insights from patients’ medical images.
We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs. We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients.
We are a game changer in the medical space. Deploying our clinical expertise, proprietary technologies, and data science experience, we generate unprecedented insights from medical images for both drug development and patient care. We bring answers to your concerns and help therapeutic decisions.
Our imaging solutions make an impact throughout the entire patient journey, from drug development to patient care.
With iCRO we offer best-in-class end-to-end image management in oncology trials. We provide our global biopharma customers with key data on patients’ response to candidate drugs from phase I through phase III studies. Imaging Lab, our enriched iCRO offering, drives drug development success with transformative AI-powered insights.
With eyonis™ we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.
Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results
The partnership’s aim is to identify predictive imaging biomarkers of patient response to a specific drug-candidate, using Imaging Lab’s unique AI capabilities. The company is a Top 10 global oncology pharmaceutical company.
Median Technologies reports its business indicators for the first half of 2024, provide an update on recent successful business achievements.
Our innovative technology and leading expertise is opening up new possibilities for biopharmaceutical companies and healthcare professionals around the world.
By successfully helping improve the lives of millions, we are delivering value for our investors and partners.
Our company is listed on Euronext Growth and our shareholding structure reflects our global reach, with major shareholders from Europe, USA, and Asia.
Being part of Median doesn’t just mean working for a company at the cutting edge of medical imaging. You become part of a team striving to improve outcomes for people suffering from life-threatening diseases. Join us!
